The Potent ITK/BTK Inhibitor Ibrutinib Is Effective for the Treatment of Experimental Visceral Leishmaniasis Caused by Leishmania donovani

BACKGROUND: New drugs are needed for leishmaniasis because current treatments such as pentavalent antimonials are toxic and require prolonged administration, leading to poor patient compliance. Ibrutinib is an anticancer drug known to modulate T-helper type 1 (Th1)/Th2 responses and has the potentia...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Infect Dis
Main Authors: Varikuti, Sanjay, Volpedo, Greta, Saljoughian, Noushin, Hamza, Omar M, Halsey, Gregory, Ryan, Nathan M, Sedmak, Bren E, Seidler, Gabriella R, Papenfuss, Tracey L, Oghumu, Steve, Satoskar, Abhay R
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Major Articles and Brief Reports
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784510/
https://ncbi.nlm.nih.gov/pubmed/30239895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiy552
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki